Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil Simplifies Class I Approvals To Focus On Higher-Risk Products

Executive Summary

Brazil has passed legislation enabling class I (lowest risk) devices and diagnostics to gain market approval through a notification pathway rather than under the current review-based registration system. The move is essentially intended to help regulatory agency Anvisa refocus its efforts toward the higher-risk arena.

You may also be interested in...



Brazil Unifies Registration Coding For Imported And Home-Produced IVDs

In vitro diagnostic (IVD) product registrations in Brazil are now subject to the same procedures and codes, irrespective of whether they are imported or manufactured in the country.

Controversial Italian COVID-19 IVDs Tender Must Not Be A Blueprint For The Future, Says Industry

Italy must ensure that ongoing efforts to tackle the coronavirus crisis do not rely on single suppliers, the country's medtech industry body said after DiaSorin looked likely to be the sole winner of a major COVID-19 diagnostics tender.

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT124775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel